Cancer Treatment
The latest news about Cancer Treatment: headlines, AI summaries and the full story from every source.
- Genmab Shares Double Following Three Successful Phase 3 Cancer Drug Trials
- Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment
- Immorta Bio Announces First Human Administration of SenoMune™-0257 Immunotherapy
- Lakefront Biotherapeutics Sells Early-Stage CAR-T Programs to Armed Cell Therapeutics
- TimeTeller Develops Saliva Test to Personalize Medicine Based on Circadian Rhythms
- Northwest Biotherapeutics partners with NHSBT to expand DCVax-L production
- AstraZeneca CEO Discusses Summit Therapeutics' Drug as a Potential Game-Changer for Cancer Treatment
- Celcuity Stock Rises on Launch of First Commercial Product
- Teva Receives FDA Approval for Biosimilar Version of Amgen's Xgeva
- Merck Withdraws BLA for Antibody-Drug Conjugate I-DXd in Small Cell Lung Cancer
- FDA Approves Merck's Welireg and Eisai's Lenvima Combination for Advanced Kidney Cancer
- Telix to Acquire ITM for Up to $2.35 Billion to Secure Cancer Isotope Supply
- BioNTech Faces Colorectal Cancer Vaccine Setback but Reports Lung Cancer Trial Success
- Revolution Medicines Receives Approval for First Product RASONQUE in Pancreatic Cancer
- Summit Therapeutics' ivonescimab shows 27% lower mortality than Merck's Keytruda in lung cancer trial
- OncoSil Medical Secures A$5.6m in Funding to Launch Cancer Treatment Device
- Summit Therapeutics' Lung Cancer Drug Shows Survival Benefit
- PMV Pharmaceuticals Raises $50.8 Million to Support Ovarian Cancer Drug Development
- Exelixis Stock Hits Record High Amid Cancer Treatment Momentum
- FDA approves first RAS-targeted pancreatic cancer drug from Revolution Medicines
- Moderna and Merck Announce Positive Phase 3 Trial Results for First mRNA Cancer Vaccine
- Moderna and Merck Report Positive Phase 3 Trial Results for mRNA Cancer Vaccine
- BioNTech Stock Rally Seen as Temporary by Analysts
- Moderna and Merck's Melanoma Therapy Meets Primary Goal in Phase 3 Trial
- Moderna and Merck's Personalized Cancer Vaccine Shows Promise in Late-Stage Melanoma Trial
- Ratio Therapeutics raises $70 million in Series C round to advance radiopharmaceutical pipeline
- Amplia Therapeutics Highlights Potential for Combination Therapy with KRAS Inhibition in Pancreatic Cancer
- Summit Therapeutics Shares Drop Despite Positive Phase 3 Data on Ivonescimab in NSCLC
- Akeso's Lung Cancer Drug Shows Improved Survival in Phase 3 Trial
- Relay Therapeutics Reports Promising Phase 2 Trial Results for Zovegalisib
- AstraZeneca's Datroway Approved as First-Line Treatment for Metastatic Triple-Negative Breast Cancer
- Merck's Lung Cancer Combo Outperforms Keytruda in Late-Stage Trial
- Merck's Sacituzumab Tirumotecan Meets Both Primary Endpoints in Phase 3 Trial for Endometrial Cancer
- Revolution (RVMD) Q1 2026 Earnings Transcript Summary
- Erasca Shares Rise on Positive Cancer Treatment Data
- Zentalis Confirms Optimal Dose for Cancer Drug; Jefferies Raises Price Target
- Eli Lilly to Acquire Kelonia Therapeutics in $7 Billion Deal